IPA announced that it has acquired the LSA instrument platform from Carterra , a provider of high-throughput large and small-molecule screening and characterization solutions. This instrument allows for high throughput surface plasmon resonance-based antibody characterizations thereby significantly increasing the Company’s capacity in performing various label-free protein interaction analyses including best-in-class kinetics, epitope binning, quantitation, epitope mapping, and blocking/neutralization assays. IPA remains committed to expanding its contract research organization CRO capabilities and leveraging technology to drive innovation and efficiency, particularly in AI-driven drug design. Carterra’s LSA instrument delivers significant throughput in short time frames requiring only small sample volumes. This fits well with the company’s established high throughput capabilities and diversity- and data-driven drug discovery, delivering huge amounts of valuable data points at an early-stage to advance the lead triaging process. The efficiency gain resulting from the acquisition will not only expedite the Company’s in vitro characterizations for clients and partners, but also rapidly fuels LENSai with valuable data sets to optimize models for next gen in silico drug discovery and development utilizing their proprietary HYFTs to aggregate and integrate biological data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
